Filing Flows › Comparisons › LUNG vs NPCE
Pulmonx vs NeuroPace: LUNG and NPCE compared
Pulmonx is the larger company: $22.8M of revenue in its latest quarter (Q3 2026) against $22.8M for NeuroPace (Q2 2026). NeuroPace is growing faster (+17% against +6% a year earlier). NeuroPace is more profitable, with an operating margin of -22.5% against -32.8%.
Where the money goes: LUNG and NPCE
Pulmonx (LUNG) · Q3 2026
Pulmonx, Q3 2026: revenue $22.8M (+6% year over year), operating margin -32.8%, net loss $8.4M, operating cash flow −$3.2M. The chart follows the revenue to costs, profit and cash.
NeuroPace (NPCE) · Q2 2026
NeuroPace, Q2 2026: revenue $22.8M (+17% year over year), operating margin -22.5%, net loss $6.2M, operating cash flow −$3.9M. The chart follows the revenue to costs, profit and cash.
| Pulmonx (LUNG) | NeuroPace (NPCE) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2026 |
| Revenue | $22.8M | $22.8M |
| Revenue growth, Y/Y | +6% | +17% |
| Operating margin | -32.8% | -22.5% |
| Net earnings | −$8.4M | −$6.2M |
| Net margin | -36.8% | -27.2% |
| Operating cash flow | −$3.2M | −$3.9M |
Questions
Which is bigger, Pulmonx or NeuroPace?
Pulmonx is the larger company: $22.8M of revenue in its latest quarter (Q3 2026) against $22.8M for NeuroPace (Q2 2026).
Is Pulmonx or NeuroPace growing faster?
NeuroPace is growing faster (+17% against +6% a year earlier).
Which is more profitable, Pulmonx or NeuroPace?
NeuroPace is more profitable, with an operating margin of -22.5% against -32.8%.
More: Pulmonx earnings · how Pulmonx makes money · NeuroPace earnings · how NeuroPace makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 3, 2026; 10-Q filed Aug 11, 2026). Fiscal quarters can end on different dates. Not investment advice.